ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effective Analysis of Antiviral Treatment in Patients with HBeAg-Seropositive Chronic Hepatitis B with ALT < 2 Upper Limits of Normal: A Multi-center Retrospective Cohort Study

Hu, Meixin; Liao, Guichan; Wei, Sufang; Qian, Zhe; Chen, Hongjie; Xia, Muye; Xie, Qiuli; Peng, Jie*南方医科大学
Infectious Diseases and Therapy2023-2DOI: 10.1007/s40121-022-00757-y
15阅读
引用收藏
分享

摘要

Introduction: Although the indications for antiviral therapy for patients with chronic hepatitis B have been gradually expanded in different guidelines, antiviral treatment efficacy remains unclear among HBeAg-seropositive patients with alanine aminotransferase (ALT) < 2 upper limits of normal (ULN). This study aimed to evaluate the efficacy of antiviral therapy for these patients.Methods: In total, 102 treatment-naive patients who were HBeAg seropositive with ALT < 2 ULN and had received nucleotide analogs were included, and their clinical data were retrospectively analyzed.Results: After 96-week treatment, 84.3% (n = 86), 26.5% (n = 27) and 20.6% (n = 21) patients achieved virological response, HBeAg seroclearance and HBeAg seroconversion, respectively. Logistic regression analysis revealed that baseline AST (odds ratio [OR] = 1.069, 95% confidence interval [CI] 1.014-1.127, p = 0.014), serum HBV DNA (OR = 0.540, 95% CI 0.309-0.946, p = 0.031) and quantitative HBsAg levels (OR = 0.147, 95% CI 0.036-0.597, p = 0.007) were independent factors for virological response. At baseline, HBsAg < 4.63 log10 IU/ml was identified as a strong predictor for the 96-week virological response, with a concordance rate of 0.902. Moreover, the levels of liver stiffness values (8.30 +/- 3.86 vs. 6.17 +/- 1.91, p < 0.001) at week 96 had significantly declined compared to baseline.Conclusion: Nucleotide analog treatment effectively suppressed HBV DNA in patients with HBeAg-seropositive chronic hepatitis B with ALT < 2 9 ULN and greatly improved liver fibrosis. The study also found that HBsAg < 4.63 log10 IU/ml was a strong predictor of the virological response.

学科与关键词

关键词
Chronic hepatitis BAntiviral therapyNormal alanine aminotransferaseVirology responseLiver fibrosis
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Infectious Diseases and Therapy
发表日期
2023-02
卷期
第 12 卷, 第 2 期
页码
637-647
DOI
10.1007/s40121-022-00757-y
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81971949]; Clinical Research Program of Nanfang Hospital, Southern Medical University [2018CR026]

作者

  • H

    Hu, Meixin (第一作者)

    southern med univ

  • L

    Liao, Guichan

    southern med univ

查看全部 8 位作者收起作者
  • W

    Wei, Sufang

    southern med univ

  • Q

    Qian, Zhe

    southern med univ

  • C

    Chen, Hongjie

    southern med univ

  • X

    Xia, Muye

    southern med univ

  • X

    Xie, Qiuli

    southern med univ

  • P

    Peng, Jie (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417